[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mayo Clinic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":563},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,570,0,25,[9,41,62,80,105,124,145,173,195,213,239,263,282,307,328,346,365,390,412,431,450,475,494,516,544],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053382","thalamus-seizure-detection-with-a-deep-brain-stimulator-system-100053382",false,"NCT06700356","Thalamus Seizure Detection With a Deep Brain Stimulator System","Seizure Detection With a Deep Brain Stimulation System","Inclusion Criteria:\n\nParticipants must meet all of the inclusion criteria to participate in this study:\n\n* 18 years of age and older.\n* Implanted with a clinical DBS system for epilepsy with brain recording capabilities (Medtronic Percept™ DBS).\n* Subject or legally authorized representative is able to understand study procedures and to comply with them for the entire length of the study.\n\nExclusion Criteria:\n\nAll candidates meeting any of the exclusion criteria at baseline will be excluded from study participation:\n\n* Health status or any clinical conditions (e.g., life expectancy, co-existing disease) that, in the opinion of the site investigator, would pose undue risk to undergo epilepsy monitoring unit evaluation for the purpose of seizure characterization.\n* Women will verify not pregnant, and if applicable, have urine pregnancy test.\n* Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.\n* Inability or unwillingness of individual or legal guardian\u002Frepresentative to give written informed consent.","ALL","18 Years",{"count":20,"type":21},5,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to determine the feasibility of chronic ambulatory thalamus seizure detection. The sensitivity, specificity, and false alarm rate of thalamus seizure detection will be calculated using recordings from a deep brain stimulation system, assessed relative to concurrent gold-standard video-EEG monitoring collected in the in-patient setting (epilepsy monitoring unit), in 5 patients with drug resistant epilepsy.",[27],"Epilepsy; Seizure","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2026-07-01",{"date":36,"type":21},"2027-05",{"name":38,"class":39},"Mayo Clinic","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":40},"100053452","comparison-of-ultrasound-and-anatomic-landmark-techniques-of-the-ulnar-and-posterior-tibial-nerves-100053452","NCT07515911","Comparison of Ultrasound and Anatomic Landmark Techniques of the Ulnar and Posterior Tibial Nerves","Inclusion Criteria:\n\n• English speaking\n\nExclusion Criteria:\n\n* History of ulnar neuropathy or ulnar nerve or wrist surgery (i.e. carpal tunnel)\n* Upper extremity edema",true,{"count":49,"type":21},40,"OBSERVATIONAL","The purpose of this study is to determine whether placement of stimulating electrodes over the ulnar nerve is important for proper delivery of current leading to stimulation of intrinsic hand muscles.",[53],"Ulnar Nerve","NOT_YET_RECRUITING","2026-07-09",{"date":31,"type":32},{"date":58,"type":21},"2026-08",{"date":60,"type":21},"2027-01",{"name":38,"class":39},{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":12,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":40},"100053496","prospective-evaluation-of-physician-modified-endografts-for-aortic-disease-100053496","NCT07611968","Prospective Evaluation of Physician Modified Endografts for Aortic Disease","Inclusion Criteria:\n\n* An aneurysm with a maximum diameter of \\>5.5cm in males and \\>5.0cm in females in diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements\n* Aneurysm with a history of growth \\> 0.5 cm in 6 months\n* Saccular aneurysm deemed at significant risk for rupture\n* Symptomatic aneurysm\n* Extent of aorta to be treated: type II, III and IV thoracoabdominal.\n* Subject is at high-risk of morbidity and mortality with open surgical repair as defined by FEV1 of \\\u003C1 liter or uncorrectable coronary disease, frailty, hostile abdomen.\n* Iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit.\n* Non-aneurysmal aortic segment proximal to the aneurysm (neck) with a:\n* Minimum neck length of 15mm\n* Diameter in the range of 17-32\n* Minimum branch vessel diameter greater than 5 mm\n* Iliac artery distal fixation site\n* An inside diameter of 8mm - 13mm and a length of ≥ 10mm or\n* an inside diameter of \\> 13mm - 20mm and a length of ≥ 15mm\n* Age: ≥50 years old\n\nExclusion Criteria:\n\n* Can be treated in accordance with the instructions for use with a legally marketed endovascular prosthesis\n* Is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site\n* Unwilling to comply with the follow-up schedule\n* Inability or refusal to give informed consent by subject or legal representative\n* Subject is pregnant or breastfeeding\n* Ruptured aneurysms\n* Prior aortic repair\n* Patient is eligible for treatment with an FDA-approved marketed device and patient can enroll in a manufacturer-sponsored clinical study at our institution or is willing and eligible to participate in a study with a manufacturer-made device at another institution.\n* Known sensitivities or allergies to the materials of construction of the devices, including nitinol, polyester, PTFE, stainless steel, platinum\u002Firidium, tantalum markers.\n* Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed\n* Uncorrectable coagulopathy\n* Body habitus that would inhibit x-ray visualization of the aorta or exceed the safe capacity of the equipment\n* Subject has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned \\\u003C 30 days of endovascular repair\n* Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina)\n* Systemic or local infection that may increase the risk of endovascular graft infection\n* Baseline creatinine greater than 2.0 mg\u002FdL\n* Thrombus or excessive calcification within the neck of the aneurysm\n* Branch stenosis \\>50% not amenable to endovascular preparation","50 Years",{"count":70,"type":21},20,[24],"The purpose of this research is to assess safety and preliminary effectiveness of the Physician-Modified Terumo Treo Abdominal Stent-Graft System.",[74],"Aortic Aneurysm",{"date":31,"type":32},{"date":29,"type":32},{"date":78,"type":21},"2028-07-15",{"name":38,"class":39},{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":20},"100605562","phase-4-azithromycin-versus-doxycycline-in-hospitalized-adult-patients-with-community-acquired-pneumonia-treated-with-beta-lactams-100605562","NCT07164131","Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams","AD-CAP","Inclusion Criteria:\n\n• All adult patients (\\>18 years old) admitted with CAP and receiving a beta-lactam antibiotic plus a form of atypical coverage (azithromycin or doxycycline) in the ED within 12 hours of admission.\n\nExclusion Criteria:\n\n* High clinical suspicion for Legionella pneumonia\n* Allergy or contraindication to the use of either azithromycin or doxycycline (usual clinical practice)\n* Antibiotics not for CAP\n* Pregnant women (based on clinical assessment as part of standard of care)\n* Severe CAP as defined by the ATS\u002FIDSA criteria\n* Corrected QT prolongation (\\> 440 ms in men and \\> 460 ms in women)\n* Receiving a different antibiotic (e.g quinolones)\n* Admission \\> 24 hours\n* Known to be a prisoner",{"count":88,"type":21},1120,[90],"PHASE4","The purpose of this study is to compare effectiveness and safety of Azithromycin versus Doxycycline in adult patients hospitalized with community acquired pneumonia (CAP) treated with Beta-lactams.",[93],"Community-acquired Pneumonia",[95,96,97],"Azithromycin","Doxycycline","hospitalized",{"date":99,"type":32},"2026-07-02",{"date":101,"type":32},"2025-09-15",{"date":103,"type":21},"2031-09-01",{"name":38,"class":39},{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":40},"100641626","virtual-group-resilient-living-program-for-patients-living-with-advanced-cancer-100641626","NCT07659158","Virtual Group Resilient Living Program For Patients Living With Advanced Cancer","Inclusion Criteria:\n\n* English fluency\n* Diagnosis of advanced (stage III\u002FIV) malignancy\n* Baseline distress score ≥ 4\u002F10. Patients can answer questions orally rather than complete worksheet, if applicable\n* Life expectancy of ≥ 6 months\n* Provide informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Has a reliable internet connection\n* Has the ability to utilize technology to watch online modules, \\& participate in virtual sessions\n\nExclusion Criteria:\n\n* As determined through self-report, those diagnosed with a history of a psychotic episode ≤ 5 years\n* All psychological co-morbidities such as a history of untreated schizophrenia, \\& bipolar disease\n* A diagnosis of severe cognitive impairment",{"count":112,"type":21},42,[24],"This study is a prospective, minimal risk, non-randomized, single-arm study to determine feasibility and assess effectiveness of a Virtual Group Resilient Living Program (RLP) on anxiety, stress, quality of life (QOL), coping, and fatigue among patients with advanced cancer. The group RLP is a psychosocial intervention that consists of a total of 7 weekly sessions in which the interventionalist teaches the patients techniques on stress management and building resilience (mindfulness, uplifting emotions, reframe experiences through principles of gratitude, compassion, acceptance, meaning, and forgiveness). The group setting allows for support and connection amongst the patients, providing further support and motivation to practice the principles of the program.",[116],"Advanced Cancer","2026-06-30",{"date":99,"type":32},{"date":120,"type":32},"2026-06-19",{"date":122,"type":21},"2027-06-30",{"name":38,"class":39},{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":40},"100594882","early-phase-1-medication-combinations-of-dasatinib-quercetin-fisetin-temozolomide-lmp744-and-autologous-tlpo-vaccine-for-the-treatment-of-previously-treated-glioma-with-residual-disease-100594882","NCT07025226","Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease","MC230715 Pilot Study of the Mechanistic Feedback From CNS Tumors With Latent Residual Disease to Guide Individualized Therapies","Senolytics","Inclusion Criteria - Treatment Arm (Regimens 1-8):\n\n* Age ≥ 18 years\n* Prior diagnosis of a glioma treated with chemotherapy and\u002For radiation with stable disease based on Response Assessment in Neuro-Oncology (RANO) criteria\n\n  * Must have IDH-mutant OR MGMT-methylated glioma\n\n    * NOTE: Patients with any radiographic evidence of residual disease are eligible\n* Eastern Cooperative Oncology Group (ECOG) of 0, 1, or 2, and Karnofsky performance status \\>= 50\n* Hemoglobin ≥ 9.0 g\u002FdL (≤ 15 days prior to registration)\n* Absolute neutrophil count (ANC) ≥ 1500\u002Fmm\\^3 (≤ 15 days prior to registration)\n* Platelet count ≥ 100,000\u002Fmm\\^3 (without transfusion ≤ 7 days preceding lab assessment) (≤ 15 days prior to registration)\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 x upper limit of normal (ULN) (or ≤ 5 x ULN for patients with liver involvement) (≤ 15 days prior to registration)\n* Calculated creatinine clearance ≥ 45 ml\u002Fmin using the Cockcroft-Gault formula (≤ 15 days prior to registration)\n* Average corrected QT interval (QTc) ≤ 450 ms on triplicate 12 lead electrocardiogram (ECG) ≤ 29 days prior to registration\n\n  * NOTE: QTc intervals will be corrected using Fridericia's formula (Fridericia 1920)\n* Negative serum pregnancy test is required for persons of childbearing potential ≤ 8 days prior to registration\n* Presence of an implanted cranial CSF access device, such as Ommaya reservoir or ventriculoperitoneal shunt\n* Willingness to provide blood and CSF samples for research\n* Co-enrollment on the neuro-oncology biorepository \\[institutional review board (IRB) 12-003458\\] for collection of research blood and CSF samples\n* Provide written informed consent\n* Willingness to return to Mayo Clinic for follow-up\n\nInclusion Criteria - Monitoring Arm (Regimen 1 only):\n\n* Age ≥ 18 years\n* Prior diagnosis of a glioma\n* Negative serum pregnancy test is required for persons of childbearing potential ≤ 8 days prior to registration\n* Co-enrollment on the neuro-oncology biorepository \\[institutional review board (IRB) 12-003458\\] for collection of research blood and CSF samples\n* Provide written informed consent\n* Willingness to return to Mayo Clinic for follow-up\n\nExclusion Criteria - Treatment Arm (Regimens 1-8):\n\n* Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential and persons able to father a child who are unwilling to employ adequate contraception\n* Patients who are not appropriate medical candidates due to current or past medical history or uncontrolled concurrent illness which limits safety of or compliance to study proceedings\n* Participants who are unable to swallow tablets or who are at risk for impaired absorption of oral medication\n\n  * NOTE: This includes but not limited to, refractory vomiting, gastric resection\u002Fbypass, or duodenal\u002Fjejunal resection\n  * NOTE: An exception can be granted for such patients if no oral medications are planned (i.e., patient will receive only IV or intradermal agents)\n* Patients with known hypersensitivity or allergy to all of the study drugs on the protocol (known hypersensitivity or allergy to one drug does not preclude participation in this protocol)\n* Inability to undergo MRI scans\n\n  * NOTE: These patients may be enrolled in the Monitoring Arm\n\nExclusion Criteria - Monitoring Arm (Regimen 1 only):\n\n* Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential and persons able to father a child who are unwilling to employ adequate contraception\n* Current or past medical history or uncontrolled concurrent illness which limits safety or compliance with study proceedings\n* Known hypersensitivity or allergy to radioactive tracers\n* Inability to undergo clinical imaging",{"count":133,"type":21},30,[135],"EARLY_PHASE1","This early phase I trial tests the safety, side effects and how well medication combinations of dasatinib, quercetin, fisetin, temozolomide, LMP744, and autologous tumor lysate particle only (TLPO) vaccine work in treating patients with glioma for which the patient has received treatment in the past (previously treated) and for tumor cells that remain after attempts to treat the tumor have been made (residual disease). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply, which may help keep tumor cells from growing. Quercetin and fisetin are compounds found in plants. They have antioxidant and anti-inflammatory properties and help remove senescent cells, older or damaged cells that have stopped dividing but don't die off as they should and build up in tissues over time. Senescent cells may cause inflammation or damage to nearby healthy cells. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. LMP744 works by interfering with a protein that tumor cells use to copy and repair their DNA. By blocking this repair process, the drug causes DNA damage so that tumor cells cannot survive. The autologous TLPO vaccine is made using material from a patient's own tumor. It delivers the tumor material to immune cells so they can learn to recognize and attack the cancer. Giving medication combinations of dasatinib, quercetin, fisetin, temozolomide, LMP744, and autologous TLPO vaccine may be safe, tolerable and\u002For effective in treating patients with previously treated glioma with residual disease.",[138],"Glioma",{"date":99,"type":32},{"date":141,"type":32},"2025-08-12",{"date":143,"type":21},"2027-09-01",{"name":38,"class":39},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":172},"100555159","phase-1-intravenous-vesicular-stomatitis-virus-in-patients-with-peripheral-t-cell-lymphoma-100555159","NCT06508463","Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic\u002FDendritic Cell Neoplasms","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Relapsed or refractory:\n\n  * Group E only: Relapsed peripheral T-cell lymphoma (PTCL) of the following histologies: peripheral T-cell lymphoma-NOS (PTCL-NOS); anaplastic large cell (ALCL), and mycosis fungoides (MF)\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\\u003C 2 times upper limit of normal (ULN) (obtained =\\\u003C 15 days prior to registration)\n* Creatinine =\\\u003C 2.0 mg\u002FdL (obtained =\\\u003C 15 days prior to registration)\n* Direct bilirubin =\\\u003C 1.5 x ULN (obtained =\\\u003C 15 days prior to registration)\n* International normalized ratio (INR)\u002Fprothrombin time (PT) and activated partial thromboplastin time (aPTT) =\\\u003C 1.5 x ULN (obtained =\\\u003C 15 days prior to registration)\n* If baseline liver disease, Child Pugh score not exceeding class A (obtained =\\\u003C 15 days prior to registration)\n* Negative pregnancy test for persons of child-bearing potential (obtained =\\\u003C 15 days prior to registration)\n* FOR T-Cell Lymphoma (TCL)\u002FB-Cell Lymphoma (BCL) ONLY: Absolute Neutrophil Count (ANC) \\>= 1,000\u002Fmicroliter (μL) (obtained =\\\u003C 14 days prior to registration)\n* FOR TCL\u002FBCL ONLY: Platelets \\>= 100,000\u002FμL (obtained =\\\u003C 14 days prior to registration)\n* FOR TCL\u002FBCL ONLY: Hemoglobin \\>= 8.5 g\u002Fdl (obtained =\\\u003C 14 days prior to registration)\n* FOR TCL\u002FBCL ONLY: Measurable disease by CT or magnetic resonance imaging (MRI): must have at least one lesion that has a single diameter of \\> 2 cm or tumor cells in the blood \\> 5 x 10\\^9\u002FL; NOTE: skin lesions can be used if the area is \\> 2 cm in at least one diameter and photographed with a ruler and the images are available in the medical record\n* Absence of active central nervous system (CNS) involvement; NOTE: pre-enrollment lumbar puncture not mandatory\n* Ability to provide written informed consent\n* Willingness to return to Mayo Clinic for follow-up\n* Life expectancy \\>= 12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n* Willing to provide mandatory biological specimens for research purposes\n\nExclusion Criteria:\n\n* Availability of and patient acceptance of curative therapy\n* Uncontrolled infection\n* Active tuberculosis or hepatitis, or chronic hepatitis\n* Any of the following prior therapies:\n\n  * Chemotherapy (IMIDs, alkylating agents, proteosome inhibitors) =\\\u003C 2 weeks prior to registration\n  * Immunotherapy (monoclonal antibodies) =\\\u003C 4 weeks prior to registration\n  * Experimental agent in case of Acute Myeloid Leukemia (AML) or TCL within 4 half-lives of the last dose of the agent\n* New York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias \\[atrial fibrillation or supraventricular tachycardia (SVT)\\]\n* Active CNS disorder or seizure disorder or known CNS disease or neurologic symptomatology; in case of AML active CNS involvement as detected by lumbar puncture or neuro-imaging (only to be done if clinically indicated)\n* Human immunodeficiency virus (HIV) positive test result or other immunodeficiency or immunosuppression\n* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-Food and Drug Administration \\[FDA\\] approved indication and in the context of a research investigation);\n\n  * NOTE: in TCL, patients may use topical emollients or corticosteroids, acetic acid soaks, etc. to control pruritus and prevent infection; no topical chemotherapy is allowed (no topical nitrogen mustard)\n* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:\n\n  * Pregnant women or women of reproductive ability who are unwilling to use effective contraception\n  * Nursing women\n  * Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment\n* ADDITIONAL EXCLUSION CRITERIA FOR GROUP E (COMBINATION WITH CEMIPLIMAB) ONLY:\n\n  * Diagnosis of AML\n  * Diagnosis of Angioimmunoblastic T-cell Lymphoma (AITL)",{"count":153,"type":21},21,[155],"PHASE1","This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with cemiplimab in patients with T-cell lymphoma. A virus, called VSV-hIFNβ-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Immunotherapy with ipilmumab and cemiplimab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.",[158,159,160,161,162,163,164],"Peripheral T Cell Lymphoma","Relapsed Peripheral T-Cell Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified","Anaplastic Large Cell Lymphoma","Mycosis Fungoides","Relapsed Anaplastic Large Cell Lymphoma","Relapsed Mycosis Fungoides","2026-06-29",{"date":34,"type":32},{"date":168,"type":32},"2024-01-05",{"date":170,"type":21},"2032-04-01",{"name":38,"class":39},2,{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":194},"100644509","haiqu-hospital-air-quality-100644509","NCT07670117","HAIQU (Hospital AIr QUality)","HAIQU (Hospital AIr QUality): Breathing Life Into Patient Care","HAIQU","Inclusion Criteria:\n\nTarget Group:\n\n* Mayo Clinic Staff working in ED with a minimum of .7 FTE in Midwest (MN and WI), Phoenix (AZ), or Jacksonville (FL) and patient contact.\n\nReference Group:\n\n* Mayo Clinic Staff working in primary care with a minimum of .7 FTE. in Rochester (MN), Phoenix (AZ), or Jacksonville (FL) and patient contact\n\nExclusion Criteria:\n\n* Any participant who does not meet either of the inclusion criteria.",{"count":182,"type":21},850,[24],"The purpose of this research is to assess whether integration of an aerosol biosensor and air quality risk assessment software that integrates into a building management system will improve indoor air quality metrics in hospital environments and reduces risk factors associated with respiratory disease transmission.",[186],"Acute Respiratory Tract Infection","2026-06-25",{"date":165,"type":32},{"date":190,"type":21},"2026-10-01",{"date":192,"type":21},"2029-09-30",{"name":38,"class":39},3,{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":17,"minAge":202,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":212,"locationsCount":40},"100606345","phase-4-uroselective-alpha-1-antagonist-to-reduce-the-incidence-and-duration-of-postoperative-urinary-retention-following-spine-surgery-100606345","NCT07174349","Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery","The Use of an Uroselective Alpha-1-antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery","Inclusion Criteria:\n\n* Cervical Laminectomy\n* Cervical Posterior Fusion\n* Cervical Anterior\u002FPosterior Fusion\n* Lumbar Laminectomy\n* Lumbar Posterolateral Fusion\n* Lumbar Interbody Fusion\n\nExclusion Criteria:\n\n* Cervical Anterior Discectomy and Fusion\n* Cervical Anterior Corpectomy\n* Cervical Posterior Discectomy\n* Cervical Foraminotomy\n* Lumbar Discectomy (METRx or Open)\n* Lumbar Foraminotomy\n* Lumbar Anterior Fusion\n* Myelopathy with bladder dysfunction\n* Patients currently taking an alpha-antagonist\n\n  o The following drugs are alpha antagonists: alfuzosin, doxazosin, prazosin, terazosin, tamsulosin, and phenoxybenzamine.\n* Patients with history of allergy or sensitivity to tamsulosin or other alpha-antagonist\n* History of prostatectomy or urologic surgery involving the bladder or urethra\n* Severe liver disease or end-stage renal disease\n* Patients taking strong inhibitors of CYP3A4\n\n  o The following drugs are strong inhibitors of CYP3A4: ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir\u002Fritonavir, lopinavir\u002Fritonavir, and conivaptan.\n* Mental disability or prisoner\n* Pregnancy (for anesthesia purposes)","35 Years",{"count":70,"type":21},[90],"The purpose of this research is to see if the use of tamsulosin can decrease both the incidence and duration of urinary retention, as well as hospital length of stay following spine surgery.",[207],"Urinary Retention Postoperative",{"date":165,"type":32},{"date":190,"type":21},{"date":211,"type":21},"2028-12-31",{"name":38,"class":39},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":224,"conditions":225,"keywords":228,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":236,"leadSponsor":238,"locationsCount":4},"100603573","phase-2-metyrapone-study-for-patients-diagnosed-with-mild-autonomous-cortisol-secretion---macs-100603573","NCT07138274","Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS","A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Metyrapone in Subjects Diagnosed With Mild Autonomous Cortisol Secretion (MACS)","Inclusion Criteria:\n\n1. Provide written informed consent.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Age ≥ 18 years\n4. Diagnosed with MACS i. at least 2 abnormal post-dexamethasone cortisol results1 mg post-dexamethasone cortisol \\>1.8 mcg\u002FdL or ii. 8 mg post-dexamethasone cortisol \\>1 mcg\u002FdL b. Historical dexamethasone suppression test results can be used if performed within 24 months prior to enrollment.\n5. Adrenal imaging phenotype consistent with benign disease (adrenal adenoma\u002Fs, macronodular or micronodular adrenal hyperplasia)\n6. At least one of the following comorbidities:\n\n   1. obesity (BMI\\>30 kg\u002Fm2)\n   2. dysglycemia\n   3. dyslipidemia\n   4. hypertension\n   5. osteopenia\n   6. osteoporosis\n   7. fragility fractures\n7. Ability to take oral medication and be willing to adhere to the study intervention regimen.\n8. For persons of childbearing potential: : agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of ≤ 5% per year during the treatment period and for 1 month after the last dose of study treatment.\n9. Stable timing for bedtime for at least one week prior to on-site study visits.\n10. History of difficulty providing blood via standard blood draw methods\n\nExclusion Criteria:\n\n1. Planned alternative therapy for MACS within 12 months after joining the study.\n2. Current use of oral exogenous glucocorticoid therapy\n3. Current use of opioid therapy \\>20 MME\u002Fday\n4. Planned use of oral exogenous glucocorticoid therapy\n5. Planned use of opioid therapy \\>20 MME\u002Fday\n6. Use of injectable glucocorticoid within 6 weeks prior to Day 1\n7. Investigator's judgement based on history\u002Fphysical examination that a comorbidity or concomitant medication may impact the hypothalamic-pituitary-adrenal axis or steroid metabolome\n8. Uncontrolled intercurrent illness including, but not limited to:\n\n   * Ongoing or active infection\n   * Symptomatic congestive heart failure\n   * Unstable angina pectoris\n   * Cardiac arrhythmia\n   * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n9. Pregnancy or lactation\n10. Known allergic reactions to metyrapone\n11. Suspected false positive post-dexamethasone cortisol results due to increased metabolism, poor absorption, or noncompliance with dexamethasone\n12. Treatment with another investigational drug or other intervention within lower than specific therapy washout period",{"count":221,"type":21},90,[223],"PHASE2","single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.",[226,227],"Mild Autonomous Cortisol Secretion (MACS)","Autonomous Cortisol Secretion (ACS)",[229,230,231,232,233],"Hypercortisolism","Cortisol excess","Cushing Syndrome","Adrenal adenoma","Adrenal hyperplasia",{"date":165,"type":32},{"date":58,"type":21},{"date":237,"type":21},"2031-12",{"name":38,"class":39},{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":262},"100590794","phase-4-comparative-effectiveness-of-migraine-preventive-medications-the-apt-comparison-study-100590794","NCT06972056","Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study","A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study","Inclusion Criteria:\n\n* Adults, 18-70 years of age at the time of enrollment\n* Migraine with aura, migraine without aura, and\u002For chronic migraine; according to ICHD-3 diagnostic criteria. (Those with daily or continuous headaches are not excluded.)\n* Migraine onset prior to 50 years of age\n* Migraine present for at least 12 months at the time of enrollment\n* At least four \"moderate to severe headache days\" per month (by patient self-report and then confirmed during four-week pre-randomization headache diary phase) A \"moderate to severe headache day\" is defined as a day during which there is a headache of moderate to severe intensity that lasts for at least four hours, or a day on which a migraine-specific acute medication is taken to treat headache.\n* If already taking a migraine preventive treatment, willing to continue with that treatment without dose change during the first 16 weeks of the study, including the 4-week run-in phase and 12-week randomized phase.\n* Not pregnant or breastfeeding\n* Women of childbearing potential must agree to use effective methods of contraception to reduce the risk of pregnancy.\n* Willingness and ability to provide informed consent.\n* Willingness and ability to complete all research visits.\n\nExclusion Criteria:\n\n* Contraindications to taking atogepant, propranolol, or topiramate.\n* Currently taking atogepant, propranolol, or topiramate\\*\n* Previously took atogepant, propranolol, or topiramate\\*\n* Unwillingness to take atogepant, topiramate, or propranolol.\n* Current use of a CGRP-targeting preventive medication or beta-blocker\n* Migraine with brainstem aura\n* Hemiplegic migraine\n* Retinal migraine\n* Migraine aura without headache (exclusively)\n* Pure menstrual migraine\n* Trigeminal autonomic cephalalgias\n* Facial neuralgias\n* Secondary headache disorders (medication overuse headache is not an exclusion)\n* Migraine preventive treatment has been started or dose has been changed within 12 weeks prior to potential enrollment.\n* Used opioids or butalbital on five or more days per month on average for at least 3 months prior to enrollment.\n* Current or past epilepsy\n* Severe hepatic impairment\n* Moderate or more severe renal impairment \\* Occasional as needed use of propranolol, currently or in the past, is not an exclusion, such as taking as needed propranolol for treatment of anxiety.","70 Years",{"count":248,"type":21},1335,[90],"This goal of this study is to compare three medications used for migraine preventive treatment.\n\nThis study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others.\n\nResearch participants will:\n\n* Be randomly assigned to one of the three medications.\n* Provide information about their migraine pattern using a daily headache diary and during research visits.",[252],"Migraine",[252,254,255],"Migraine with aura","Migraine prevention",{"date":165,"type":32},{"date":258,"type":32},"2025-07-09",{"date":260,"type":21},"2029-12-01",{"name":38,"class":39},35,{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":40},"100501264","phase-2-a-study-of-magnesium-and-bladder-spasms-following-ambulatory-urologic-procedures-100501264","NCT05806996","A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures","Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures","Inclusion Criteria:\n\n\\- Be undergoing a bladder invasive procedure with or without planned urinary catheter on Mayo Clinic Gonda 7 Outpatient Procedure Center.\n\nExclusion Criteria:\n\n* Are unable to grant informed consent or comply with study procedure.\n* Allergy or known sensitivity to magnesium or Renacidin.\n* Expected or high risk of bladder extravasation.\n* Ongoing atrial fibrillation prior to surgery.\n* Are undergoing emergency surgery.\n* Are pregnant.\n* Known hypermagnesemia.\n* Patients with neuromuscular weakness (e.g., Myasthenia gravis) due to magnesium's muscle weakening effect.\n* Patients with myocardial compromise or cardiac conduction defects because of magnesium's anti-inotropic effects.\n* Patients with renal insufficiency, glomerular filtration rate less than 30, since Magnesium is eliminated by the kidneys resulting in exaggerated rise in serum magnesium.\n* Patients with concomitant use of a calcium channel blocker since magnesium sulfate could act synergistically to suppress muscular contractility.",{"count":271,"type":21},120,[223],"This research is being done to find out whether intravenous magnesium is effective in the treatment of bladder spasms after urologic surgery.",[275],"Bladder Spasms",{"date":165,"type":32},{"date":278,"type":32},"2023-07-31",{"date":280,"type":21},"2026-12-31",{"name":38,"class":39},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":22,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":304,"leadSponsor":306,"locationsCount":40},"100628937","phase-1-retifanlimab-with-or-without-difluoromethylornithine-for-the-treatment-of-progressive-high-grade-gliomas-100628937","NCT07468136","Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas","Phase I\u002FIIa Trial of Retifanlimab and Difluoromethylornithine (DFMO) in Patients With Progressive High-Grade Glioma","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of high-grade glioma, including any of the following:\n\n  * Glioblastoma, IDH-wild type (WT)\n  * Grade 3 or 4 IDH1\u002F2 mutant astrocytoma or\n  * Grade 3 oligodendroglioma\n  * Any prior grade 2 astrocytoma or oligodendroglioma that is suspected to have recurred at a higher grade\n  * Other high-grade glioma\n* Plan for surgical resection as part of routine clinical care\n* Radiographic disease progression, with or without tissue confirmation\n* Measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2 and Karnofsky Performance Status (KPS) ≥ 60\n\n  * NOTE: PS must be assessed (again) within 7 days prior to first dose of study drug\n* Hemoglobin ≥ 9.0 g\u002FdL (obtained ≤ 15 days prior to registration)\n* Absolute neutrophil count (ANC) ≥ 1500\u002Fmm\\^3 (obtained ≤ 15 days prior to registration)\n* Platelet count ≥ 100,000\u002Fmm\\^3 (obtained ≤ 15 days prior to registration)\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 15 days prior to registration)\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement) (obtained ≤ 15 days prior to registration)\n* Calculated creatinine clearance ≥ 45 ml\u002Fmin using the Cockcroft-Gault formula (obtained ≤ 15 days prior to registration)\n* Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only\n* Provide written informed consent for the current study\n* Willing to provide consent for the Neuro-oncology biorepository (IRB 12-003458) for archiving of tissue, cerebrospinal fluid (CSF), and\u002For blood samples\n* Ability to complete forms by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Any of the following because this study involves an investigational agent, the genotoxic, mutagenic, and teratogenic effects of which on the developing fetus and newborn are unknown:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential or able to father a child who are unwilling to employ adequate contraception\n* Uncontrolled intercurrent illness that by the judgement of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the regimens including, but not limited to:\n\n  * ongoing or active infection (e.g., pneumonia, sepsis, etc.) requiring systemic therapy\n  * current diagnosis or previous history of immune-related (non-infectious) pneumonitis or interstitial lung disease that requires or required steroids\n  * active autoimmune disease that required systemic treatment other than replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroids) ≤ 2 years prior to registration\n  * symptomatic congestive heart failure\n  * unstable angina pectoris\n  * psychiatric illness\u002Fsocial situations that would limit compliance with study requirements (e.g., drug addiction)\n  * concurrent active Hepatitis B (defined as hepatitis B surface antigen \\[HBsAg\\] positive and\u002For detectable hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\]) and Hepatitis C virus (defined as anti-hepatitis C virus \\[HCV\\] antibody \\[Ab\\] positive and detectable HCV ribonucleic acid \\[RNA\\]) infection\n\nEXCEPTIONS:\n\n* Patients with evidence of hepatitis B virus (HBV) infection (HBsAg positive) must have completed at least 4 weeks of HBV antiviral therapy, and the HBV viral load must be undetectable at the time of registration\n* Patients with a history of hepatitis C virus (HCV) are eligible if they have an undetectable HCV viral load. Patients must have completed curative anti-viral treatment ≥ 4 weeks prior to registration.\n\n  * NOTE: Patients without symptoms or prior history do not require testing prior to registration\n\n    * Co-morbid systemic illnesses or other severe concurrent disease that would make the patient inappropriate for entry into the study or interfere with proper assessment of safety and toxicity\n    * History of myocardial infarction ≤ 6 months prior to registration or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias\n    * Active autoimmune disease that has required systemic treatment (other than replacement therapy) ≤ 1 year prior to registration\n    * History of allogeneic stem cell transplant\n    * Receiving any other investigational agent with therapeutic intent\n    * Participants who are unable to swallow the DFMO solution or who are at risk for impaired absorption of oral medication.\n* NOTE: This restriction includes, but is not limited to, refractory vomiting, gastric resection\u002Fbypass, and duodenal\u002Fjejunal resection\n\n  * Patients with known hypersensitivity or allergy to DFMO or retifanlimab\n  * Contraindication to MRI or administration of gadolinium",{"count":290,"type":21},33,[155,223],"This phase I\u002FII trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse (progressive). Immunotherapy with monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. DFMO is in a class of medications called ornithine decarboxylase (ODC) inhibitors. It works by blocking the action of a substance that signals tumor cells to multiply. This helps stop or slow the spread of tumor cells. Giving retifanlimab with or without DFMO mat be safe, tolerable and\u002For effective in treating patients with progressive high grade glioma.",[294,295,296,297,298,299],"Anaplastic Oligodendroglioma","Astrocytoma, IDH-Mutant, Grade 3","Astrocytoma, IDH-Mutant, Grade 4","Diffuse Astrocytoma","Glioblastoma, IDH-Wildtype","Malignant Glioma","2026-06-23",{"date":302,"type":32},"2026-06-24",{"date":300,"type":32},{"date":305,"type":21},"2030-10-25",{"name":38,"class":39},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":194},"100608825","minimally-invasive-approaches-for-the-diagnosis-of-barretts-esophagus-and-esophageal-cancer-sos5c-trial-100608825","NCT07206589","Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial","Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma- R01 Aim 1a Renewal (SOS5C Trial)","Inclusion Criteria:\n\n* SPECIFIC AIM 1A: Adult patients 18-85 years old\n* SPECIFIC AIM 1A INTERVENTION CLUSTERS: BE Risk Tool Score \\> 0.087, indicating a higher risk for BE\u002Fesophageal adenocarcinoma (EAC). This will be run as a web-based application integrating data from several domains in the electronic health record (EPIC). Output score will range from 0-1.\n* SPECIFIC AIM 1A CONTROL CLUSTERS: Meeting American College of Gastroenterology (ACG) screening criteria (gastroesophageal reflux disease \\[GERD\\]+ \\> 2 BE risk factors: Age ≥ 50 years, Male sex, Caucasian race, obesity \\[body mass index (BMI) \\> 30\\], ever smoker, family history of BE\u002FEAC)\n* SPECIFIC AIM 1B: A \"low risk\" BE risk tool score (\\\u003C 0.0897)\n\nExclusion Criteria:\n\n* SPECIFIC AIM 1A: History of Barrett's esophagus or esophageal adenocarcinoma\n* SPECIFIC AIM 1A: Prior endoscopy in the last 10 years\n* SPECIFIC AIM 1A: Patients who are unable to consent\n* SPECIFIC AIM 1A: Patients with a current history of uninvestigated dysphagia\n* SPECIFIC AIM 1A: History of eosinophilic esophagitis, achalasia\n* SPECIFIC AIM 1A: Patients on oral anticoagulation including Coumadin, Warfarin unless discontinued for five days prior to the sponge procedure\n* SPECIFIC AIM 1A: Patients on antiplatelet agents including Clopidogrel, unless discontinued for five days prior to the sponge procedure\n* SPECIFIC AIM 1A: Patients on oral thrombin inhibitors including Dabigatran and oral factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban, unless discontinued for five days prior to the sponge procedure\n* SPECIFIC AIM 1A: Patients with a history of known varices or cirrhosis\n* SPECIFIC AIM 1A: Patients with a history of esophageal or gastric resection for esophageal or gastric carcinoma\n* SPECIFIC AIM 1A: Patients with congenital or acquired bleeding diatheses\n* SPECIFIC AIM 1A: Patients with a history of esophageal squamous dysplasia or esophageal squamous carcinoma\n* SPECIFIC AIM 1A: Patients with limited life expectancy (\\\u003C 2 years): per provider judgement\n* SPECIFIC AIM 1B: History of Barrett's esophagus or esophageal adenocarcinoma\n* SPECIFIC AIM 1B: Prior endoscopy in the last 10 years\n* SPECIFIC AIM 1B: Patients who are unable to consent\n* SPECIFIC AIM 1B: Patients with a current history of uninvestigated dysphagia\n* SPECIFIC AIM 1B: History of eosinophilic esophagitis, achalasia\n* SPECIFIC AIM 1B: Patients on oral anticoagulation including Coumadin, Warfarin unless discontinued for five days prior to procedure\n* SPECIFIC AIM 1B: Patients on antiplatelet agents including Clopidogrel, unless discontinued for five days prior to procedure\n* SPECIFIC AIM 1B: Patients on oral thrombin inhibitors including Dabigatran and oral factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban, unless discontinued for five days prior to procedure\n* SPECIFIC AIM 1B: Patients with a history of known varices or cirrhosis\n* SPECIFIC AIM 1B: Patients with a history of esophageal or gastric resection for esophageal or gastric carcinoma\n* SPECIFIC AIM 1B: Patients with congenital or acquired bleeding diatheses\n* SPECIFIC AIM 1B: Patients with a history of esophageal squamous dysplasia or esophageal squamous carcinoma\n* SPECIFIC AIM 1B: Patients with limited life expectancy (\\\u003C 2 years): per provider judgement","85 Years",{"count":316,"type":21},1010,[24],"This clinical trial studies how well minimally invasive approaches (an artificial intelligence \\[AI\\] powered risk tool, nurse navigation, and a sponge on a string \\[SOS\\] test) work in diagnosing patients with Barrett's esophagus (BE) and esophageal cancer. Esophageal cancer has a poor 5-year survival rate when diagnosed after onset of symptoms. While rising, incidence of esophageal cancer remains too low to screen the entire population. BE is a condition in which the cells lining the lower part of the esophagus have changed or been replaced with abnormal cells that could lead to esophageal cancer. Currently, patients are screened for BE based on certain risk factors (reflux, age \\> 50 years, White race, family history of esophageal cancer, obesity, male sex, and smoking), followed by endoscopies and surgery for treatment. These standard procedures may result in under-recognition of BE risk due to inaccurate and difficult to use risk assessment tools, high cost, invasiveness, low access to endoscopy, and sub-optimal recognition of abnormal cells during routing endoscopy. An AI powered risk tool that integrates symptoms, health history, and laboratory values from electronic health record data may more accurately assess BE and esophageal cancer risk that manual assessment. The BE-SOS screening test combines a swallowable cell collection device with assessment of DNA, which may more accurately diagnose abnormal cells. Nurse navigation involves trained personnel assisting individuals through the screening process and completing the follow-up diagnostic test if the screening test is positive. Navigators address cultural, social, access, and logistical barriers to screening. Nurse navigation may increase completion rates of diagnostic procedures following a positive screening test. These minimally invasive approaches may enable higher rates of BE screening than currently being accomplished.",[320,321],"Barrett Esophagus","Esophageal Adenocarcinoma",{"date":302,"type":32},{"date":324,"type":21},"2026-12-01",{"date":326,"type":21},"2030-07-31",{"name":38,"class":39},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":345,"locationsCount":172},"100602238","augmented-reality-real-time-guidance-for-mri-guided-interventions-100602238","NCT07120906","Augmented Reality Real-Time Guidance for MRI-Guided Interventions","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, ages 18-90 years\n* Patient referred to Interventional Radiology for image-guided liver needle placement for ablation\u002Fbiopsy.\n\nExclusion Criteria:\n\n* Patients who are unable to give informed consent themselves or through their parents.\n* Patients that do not fit into MR scanner (70 cm bore) with room for needle placement.\n* Contraindications to MRI such as MR-unsafe implants.","90 Years",{"count":70,"type":21},[24],"The purpose of this research is to evaluate the safety and feasibility of using a needle guidance system (LUMENA) create by CLEAR GUIDE MEDICAL for needle placement for biopsy or liver tumor ablation procedures.",[339],"Liver",{"date":341,"type":32},"2026-06-26",{"date":343,"type":32},"2025-07-25",{"date":280,"type":21},{"name":38,"class":39},{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":194},"100325407","phase-2-acalabrutinib-with-or-without-obinutuzumab-in-treating-patients-with-early-stage-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-100325407","NCT03516617","Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL) Who Are at High Risk of Disease Progression","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Diagnosis of:\n\n  * Biopsy-proven small lymphocytic lymphoma (SLL) , or\n  * Diagnosis of chronic lymphocytic leukemia (CLL) with a clonal B-cell population in the peripheral blood with immunophenotyping consistent with CLL as follows:\n\n    * The population of lymphocytes share both B-cell antigens (CD19, CD20 \\[typically dim expression\\], or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc.)\n    * Clonality as evidenced by kappa or lambda light chain expression (typically dim immunoglobulin expression) or other genetic method (e.g. IGHV analysis)\n    * Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative fluorescence in situ hybridization (FISH) analysis for t(11;14)(IgH\u002FCCND1)\n* Patients must be previously untreated\n\n  * Note: Prior chemotherapy or monoclonal antibody based therapy for treatment of CLL or SLL will be considered prior therapy; nutraceutical treatments with no established benefit in CLL (such as epigallocatechin gallate or EGCG, found in green tea or other herbal treatments or supplemental vitamins) will not be considered \"prior treatment\"; prior corticosteroid therapy for an indication other than CLL\u002FSLL will not be considered \"prior treatment\"\n* All patients will undergo testing for prognostic factors according to the CLL-IPI (testing obtained =\\\u003C 730 days prior to registration)\n\n  * Note: If the results for any of the prognostic factors included in the CLL-IPI are unknown including IGVH mutation status results not being available due to a failed laboratory assay, the patient is not eligible\n  * Note: When determining CLL-IPI, use most recent test results, if more than one result is available\n  * Note: Patients with CLL-IPI risk category of high risk or very high risk (total score of 4-10) will be randomized to Arms A or B\n  * Note: Patients with CLL-IPI risk category of low risk or intermediate risk (total score of 0-3) will be registered to Arm C\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n* Provide written informed consent\n* Willing to provide blood and saliva samples for correlative research purposes\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* For high risk and very high risk CLL-IPI (Arms A and B) only: Absolute neutrophil count (ANC) \\>= 1500\u002Fmm\\^3 (obtained =\\\u003C 30 days prior to randomization)\n* For high risk and very high risk CLL-IPI (Arms A and B) only: Platelet count \\>= 100,000\u002Fmm\\^3 (obtained =\\\u003C 30 days prior to randomization)\n* For high risk and very high risk CLL-IPI (Arms A and B) only: Hemoglobin \\>= 11.0 g\u002FdL (obtained =\\\u003C 30 days prior to randomization)\n* For high risk and very high risk CLL-IPI (Arms A and B) only: Aspartate aminotransferase (aspartate transaminase \\[AST\\]) =\\\u003C 3 x upper limit of normal (ULN) (obtained =\\\u003C 30 days prior to randomization)\n* For high risk and very high risk CLL-IPI (Arms A and B) only: Creatinine =\\\u003C 1.5 X ULN (obtained =\\\u003C 30 days prior to randomization)\n* For high risk and very high risk CLL-IPI (Arms A and B) only: Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN) (or total bilirubin =\\\u003C 3.0 x ULN with direct bilirubin =\\\u003C 1.5 x ULN in patients with well-documented Gilbert's syndrome (obtained =\\\u003C 30 days prior to randomization)\n* For high risk and very high risk CLL-IPI (Arms A and B) only: Prothrombin time (PT), international normalized ratio (INR), and partial thromboplastin time (PTT) =\\\u003C 1.5 X ULN OR if patient is receiving anticoagulant therapy and PT or PTT is within therapeutic range of intended use of coagulants (obtained =\\\u003C 30 days prior to randomization)\n* Negative serum pregnancy test done =\\\u003C 7 days prior to registration, for persons of childbearing potential only\n* Will provide bone marrow aspirate sample for correlative research purposes\n\nExclusion Criteria:\n\n* Date of CLL\u002FSLL diagnosis \\>= 24 months prior to registration\n* Prior exposure to ibrutinib or to a BCR inhibitor (e.g. Btk or PI3 kinase or Syk inhibitors) or a BCL-2 inhibitor (e.g. venetoclax)\n* Known central nervous system (CNS) lymphoma or leukemia\n* Patients with any of the following indications for chemotherapy:\n\n  * Evidence of progressive marrow failure as manifested by the development of or worsening anemia (=\\\u003C 11 g\u002FdL) and\u002For thrombocytopenia (=\\\u003C 100 x 10\\^9\u002FL) not due to autoimmune disease\n  * Symptomatic or progressive lymphadenopathy, splenomegaly or hepatomegaly\n  * One or more of the following disease-related symptoms:\n\n    * Weight loss \\>= 10% within the previous 6 months\n    * Extreme fatigue attributed to CLL\n    * Fevers \\>= 100.4 degrees Fahrenheit (F) for 2 weeks without evidence of infection\n    * Drenching night sweats without evidence of infection\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n* Other active malignancy =\\\u003C 2 years prior to registration; EXCEPTIONS: Non-melanotic skin cancer, carcinoma-in-situ of the cervix, or early stage prostate cancer\n* History of myocardial infarction =\\\u003C 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias\n* For high risk and very high risk CLL-IPI (Arms A and B) only:\n\n  * Any of the following:\n\n    * Pregnant persons\n    * Nursing persons\n    * Persons of childbearing potential who are unwilling to employ highly effective contraception\n  * Serologic status reflecting active hepatitis B or C infection\n\n    * NOTE: Subjects with hepatitis B core antibody positive who are surface antigen negative or who are hepatitis C antibody positive will need to have a negative polymerase chain reaction (PCR) result before randomization; those who are hepatitis B surface antigen positive or hepatitis B PCR positive and those who are hepatitis C PCR positive will be excluded\n  * History of stroke or intracranial hemorrhage within 6 months before randomization\n  * History of bleeding diathesis (e.g. hemophilia, von Willebrand disease)\n  * Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g. phenprocoumon) within 7 days of first dose of study drug and while on study\n  * Requires treatment with a strong CYP3A inducer\n  * Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening\n  * History of confirmed progressive multifocal leukoencephalopathy (PML)\n  * Received a vaccination with a live vaccine =\\\u003C 28 days prior to randomization",{"count":271,"type":21},[223],"This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.",[357,358],"Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma",{"date":302,"type":32},{"date":361,"type":32},"2018-09-10",{"date":363,"type":21},"2030-10-16",{"name":38,"class":39},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":372,"minAge":373,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":40},"100644342","flyte-device-for-improving-urinary-incontinence-among-endometrial-and-cervical-cancer-survivors-who-have-undergone-radiation-therapy-100644342","NCT07662824","Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy","Flyte System Transvaginal Mechanotherapy for Urinary Incontinence in Endometrial and Cervical Cancer Survivors: A Pilot Study","Inclusion Criteria:\n\n* Female patients who have received conventionally fractioned adjuvant or primary pelvic radiation therapy for endometrial or cervical cancer ≥ 3 months prior to registration\n* Age ≥ 21 years at enrollment\n* English speaking\n* Demonstrates understanding of the study protocol and has signed the Informed Consent Form (ICF)\n* Has a clinical diagnosis of urinary incontinence (stress urinary incontinence \\[SUI\\], urge urinary incontinence \\[UUI\\], mixed) or overactive bladder (OAB)\n* Ability to contract the pelvic floor muscles (PFMs) without pain\n* Ability to tolerate size 6 vaginal dilator\n* Internet access\n* Access to an iOS or Android smartphone or tablet with capabilities to download and use the Flyte app\n* Willing and able to participate in follow-up\n\nExclusion Criteria:\n\n* Participation in another clinical study which may interfere with study requirements\n* Currently receiving active cancer directed therapy (i.e., cytotoxic chemotherapy) in post hysterectomy patients\n* Completion of radiation therapy or surgery within 3 months of enrollment\n* Life expectancy is less than six months in the opinion of the investigator\n* Inability to tolerate insertion of the intravaginal wand. This will be recorded to support the usability of Flyte secondary endpoint\n* Suspected vesicovaginal or colovaginal fistula\n* Physical limitations that impede the patient's ability to participate (e.g., ability to grasp the wand and insert it and ability to turn on the Flyte controller unit)\n* Acute infection or hematuria\n* Inability to contract the PFMs or pain with contraction, as confirmed with intravaginal exam\n* Impaired cognitive function or neurologic conditions","FEMALE","21 Years",{"count":375,"type":21},44,[24],"This clinical trial studies how well and how easy it is to use a device called Flyte in improving problems with bladder control (urinary incontinence) among endometrial and cervical cancer survivors who have undergone radiation therapy. Urinary incontinence is common after pelvic radiation therapy and can affect daily life and well-being. Access to in-person pelvic floor physical therapy can be limited. The Flyte device is designed for in-home use to deliver a series of mechanical vibrations at a specific frequency while the pelvic floor muscles are contracting and relaxing (i.e., normal, guided Kegel exercises). This treatment is called mechanotherapy. The Flyte device may improve urinary incontinence symptoms, as well as overall quality of life among endometrial and cervical cancer survivors who have undergone radiation therapy.",[379,380,381,382],"Cervical Carcinoma","Endometrial Carcinoma","Overactive Bladder","Voiding Disorders","2026-06-22",{"date":300,"type":32},{"date":386,"type":21},"2026-08-13",{"date":388,"type":21},"2028-08-13",{"name":38,"class":39},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":47,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":22,"phases":399,"briefSummary":400,"conditions":401,"keywords":403,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":411,"locationsCount":40},"100596232","satisfaction-and-feasibility-evaluation-of-an-electronic-massager-compared-to-massage-therapist-delivered-massage-100596232","NCT07042776","Satisfaction and Feasibility Evaluation of an Electronic Massager Compared to Massage Therapist-delivered Massage","Satisfaction and Feasibility Evaluation of an Electronic Massager (Expert Manipulative Massage Automation -EMMA) Compared to Massage Therapist-delivered Massage","EMMA2","Inclusion Criteria:\n\n* Age 18 years or older\n* Ability to provide informed consent\n* Women of childbearing potential who self-report not being pregnant and agree to employ an effective method of birth control (surgical sterilization or oral contraceptives, barrier method with spermicides, intrauterine device, etc.) during the study period\n* Ability to complete all aspects of this trial\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Patients with inability of staying in a prone position\n* Patients with bleeding disorders\n* Patients with a current diagnosis of cancer or being treated for cancer\n* Patients with allergies and\u002For local skin affectations\n* An unstable medical or mental health condition as determined by the physician investigator",{"count":70,"type":21},[24],"The objective of this study is to evaluate the practicality and acceptability of using an electronic massager. Additionally, it aims to compare user satisfaction between the experience with an electric massager and a massage provided by a professional massage therapist.",[402],"Massage Therapy",[404,405,402,406],"EMMA","Expert Manipulative Massage Automation","EMMA@TREATMENT",{"date":187,"type":32},{"date":409,"type":32},"2026-01-02",{"date":280,"type":21},{"name":38,"class":39},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":22,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":40},"100576447","phase-1-elotuzumab-daratumumab-iberdomide-and-dexamethasone-for-the-treatment-of-relapsed-multiple-myeloma-100576447","NCT06785415","Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma","Phase 1\u002F2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of signing the informed consent form (ICF).\n* Diagnosis of relapsed multiple myeloma with ≤ 3 prior lines of therapy including treatment with proteasome inhibitors (i.e., ixazomib, carfilzomib, bortezomib), immunomodulatory imide drugs (i.e., lenalidomide, pomalidomide), and anti-CD38 drugs (i.e., daratumumab, isatuximab). Patients are required to have received a proteasome inhibitor, immunomodulatory imide drug, or combination of the two drug classes during first-line treatment.\n\n  * Note: Prior treatment with iberdomide is not allowed. Patients should not be refractory simultaneously to all other drugs in the combination.\n* Measurable disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2.\n* Hemoglobin ≥ 8.0 g\u002FdL (obtained ≤14 days prior to registration).\n* Absolute neutrophil count (ANC) ≥ 1000\u002Fm\\^3 (obtained ≤14 days prior to registration).\n* Platelet count ≥ 50,000\u002Fmm\\^3. Note: It is not permissible to transfuse subjects to achieve minimum platelet counts (obtained ≤14 days prior to registration).\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (≤ 3 x ULN for patients with Gilbert's syndrome) (obtained ≤14 days prior to registration).\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2 x ULN and alkaline phosphatase ≤ 1.5 x ULN (obtained ≤14 days prior to registration).\n* Calculated creatinine clearance ≥ 30 ml\u002Fmin using the Cockcroft-Gault (obtained ≤14 days prior to registration).\n* Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only. Note: A person of childbearing potential (PCBP) is a person who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) and must:\n\n  * Have 2 negative pregnancy tests prior to starting study treatment and must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact.\n\nAND\n\n* Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with two forms of contraception: one highly effective, and one additional effective (barrier) measure of contraception without interruption 28 days prior to starting investigational product, during the study treatment, and for at least 28 days after the last dose of iberdomide, 90 days after the last dose of daratumumab, 7 months after last dose of elotuzumab whichever is longer.\n* NOTE: Non-childbearing potential is defined as follows (by other than medical reasons):\n\n  * ≥ 45 years of age and has not had menses for \\> 24 months.\n  * Patients who have been amenorrhoeic for \\\u003C 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation.\n  * Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.\n\n    * Willingness to follow Pregnancy Prevention Program requirements:\n* Persons of childbearing potential must agree to use a contraceptive method that is highly effective (with a failure rate of \\\u003C 1% per year), preferably with low user dependency, during the intervention period and for at least 7 months after the last dose of study intervention. These patients must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period.\n* Persons able to father a child must agree that during the treatment intervention period and for 6 months after the last dose of study treatment (to allow for clearance of any altered sperm), the participant will:\n\n  * Refrain from donating sperm while on study treatment, during dose interruptions and for at least 6 months following last dose of study treatment, PLUS either:\n  * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, OR,\n  * Must agree to use contraception\u002Fbarrier such as a male condom (even if they have undergone successful vasectomy), and when having sexual intercourse with a person of childbearing potential who is not currently pregnant his partner will use an additional highly effective contraceptive method with a failure rate of \\\u003C 1% per year.\n\n    * Provide written informed consent.\n    * Willingness to provide mandatory bone marrow specimens for correlative research.\n    * Willing and able to adhere to the study visit schedule and other protocol requirements. Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).\n    * Willing to refrain from donating blood while on study treatment, during dose interruptions and for at least 28 days following the last dose of study treatment.\n\nExclusion Criteria:\n\n* Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception.\n* Receiving any other concurrent chemotherapy, or any ancillary therapy considered investigational.\n\n  * Note: Bisphosphonates are supportive care rather than therapy and are thus allowed while on protocol treatment.\n* Known to be human immunodeficiency virus (HIV) positive known or suspected active hepatitis C infection or seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen \\[HBsAg\\]) at registration or ≤ 3 months prior to registration.\n\n  * Note: Participants with resolved hepatitis B infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen \\[anti-HBc\\] and\u002For antibodies to hepatitis B surface antigen \\[anti-HBs\\]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded.\n  * EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.\n* Evidence of cardiovascular disease risk, as defined by any of the following:\n\n  * Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant electrocardiogram (ECG) abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block\n  * History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting ≤ three (3) months prior to registration.\n  * Class III or IV heart failure as defined by the New York Heart Association functional classification system \\[NYHA, 1994\\]\n  * Uncontrolled hypertension\n  * History of life-threatening ventricular arrhythmias.\n* Known moderate or severe persistent asthma, or currently has uncontrolled asthma of any classification.\n* Unable or unwilling to undergo protocol required thromboembolism prophylaxis.\n* Has taken a strong inhibitor or inducer of CYP3A4\u002F5 including grapefruit, St. John's Wort or related products ≤ 14 days prior to registration.\n* Known allergy to any of the study medications, their analogues or excipients in the various formulations.\n* Major surgery ≤ 14 days prior to registration.\n* Has been treated with an investigational agent (i.e., an agent not commercially available) ≤ 28 days or 5 half-lives (whichever is longer) prior to registration.\n* Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.\n* Any co-morbidity which would interfere with patient's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease.\n* History of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, or pomalidomide.\n* Peripheral neuropathy grade ≥ 2.\n* Severe acute respiratory syndrome coronavirus 2 infection ≤ 14 days prior to registration for mild or asymptomatic infections OR ≤ 28 days prior to registration for severe\u002Fcritical illness.\n* Gastrointestinal disease that may significantly alter the absorption of iberdomide.\n* Received a live vaccine ≤ 90 days prior to registration.\n* Prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years with the exception of the following noninvasive malignancies:\n\n  * Basal cell carcinoma of the skin\n  * Squamous cell carcinoma of the skin in situ (stage 0)\n  * Carcinoma in situ of the cervix\n  * Carcinoma in situ of the breast\n  * Incidental histologic finding of prostate cancer (T1a or T1b using the TNM \\[tumor, nodes, metastasis\\] clinical staging system) or prostate cancer that is curative.\n* Received hydroxychloroquine, quinacrine, chloroquine, methotrexate, leflunomide, sulfasalazine, mycophenolate mofetil, mycophenolic acid ≤ 28 days prior to registration.\n* Received daily nonsteroidal anti-inflammatory drugs (NSAIDs) ≤ 14 days prior to registration. Note: Allowed if dose has been stable for at least 14 days.\n* Received immunomodulating or immunosuppressive therapy as follows:\n\n  * Etanercept ≤ 28 days prior to registration\n  * Belimumab ≤ 12 weeks prior to registration\n  * B-cell depleting or modulating agents (such as rituximab or anti-CD22 therapy) ≤ 365 days prior to registration.",{"count":420,"type":21},37,[155,223],"This phase I\u002FII trial tests the safety, side effects, and best dose of iberdomide and how well it works in combination with daratumumab, elotuzumab, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Elotuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving iberdomide in combination with daratumumab, elotuzumab, and dexamethasone may be safe, tolerable and\u002For effective in patients with relapsed multiple myeloma.",[424],"Recurrent Multiple Myeloma",{"date":187,"type":32},{"date":427,"type":32},"2025-03-18",{"date":429,"type":21},"2031-04-01",{"name":38,"class":39},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":440,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":194},"100644502","acute-kidney-injury-in-care-transitions-act-pragmatic-clinical-trial-100644502","NCT07670520","Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial","ACT","Inclusion Criteria:\n\n* Clinician subjects\n\n  * Hospital clinicians including physicians and advanced practice providers employed by Mayo Clinic and practicing at one of the four study sites\n  * Provide care for hospitalized patients with stage 2 or stage 3 acute kidney injury (AKI) who are expected to be discharged home and are not receiving dialysis\n* Patient subjects:\n\n  * Adults ≥18 years old\n  * Meet KDIGO consensus criteria for stage 2 (moderate) or 3 (severe) AKI\n  * Residence within the study catchment area (southern Minnesota, northern Iowa, or western Wisconsin)\n\nExclusion Criteria:\n\n* Clinician subjects: Physicians and advanced practice providers who:\n\n  * Care exclusively for pediatric patients (\\\u003C18 years)\n  * Care exclusively for patients on palliative care\n* Patient subjects\n\n  * Discharged to hospice care\n  * Require outpatient dialysis at discharge\n  * Are admitted from or expected to be discharged to a skilled nursing facility\n  * Dementia Diagnosis\n  * Have undergone solid organ transplant within the past 100 days\n  * Decline authorization for use of their medical records for research",{"count":439,"type":21},2260,[24],"The purpose of this study is to determine the effect of a multidisciplinary intervention at care transitions for acute kidney injury survivors on patient-centered outcomes.",[443],"Acute Kidney Injury",{"date":341,"type":32},{"date":446,"type":32},"2026-04-16",{"date":448,"type":21},"2030-12-31",{"name":38,"class":39},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":47,"sex":372,"minAge":18,"maxAge":457,"enrollmentInfo":458,"targetDuration":460,"studyType":50,"phases":4,"briefSummary":461,"conditions":462,"keywords":466,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":40},"100584679","breastmilk-in-response-to-a-bout-of-exercise-100584679","NCT06892483","Breastmilk in Response to a Bout of Exercise","Breastmilk Composition in Response to a Bout of Exercise","Exclusion Criteria:\n\n* Active coronary artery disease or heart failure.\n* Participation in a structured exercise program ≥ 1 day\u002Fweek in the \"inactive\" subcohort or \\\u003C 3 days per week in the \"active\" subcohort.\n* A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:\n\n  * Abnormal liver function test results (Transaminase \\>2 times the upper limit of normal\n  * Abnormal renal function test results (calculated GFR \\\u003C60 mL\u002Fmin\u002F1.73m2);\n  * If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study\n  * Uncontrolled thyroid disease (TSH undetectable or \\>10 mlU\u002FL); testing required within three months prior to admission for subjects with a goiter, positive antibodies, or who are on thyroid hormone replacement, and within one year otherwise\n  * Abuse of alcohol or recreational drugs\n  * Active tobacco smoking within the past 3 months\n  * Infectious process not anticipated to resolve prior to study procedures (e.g. meningitis, pneumonia, osteomyelitis).\n  * Uncontrolled arterial hypertension (Resting diastolic blood pressure \\>90 mmHg and\u002For systolic blood pressure \\>160 mmHg) at the time of screening.\n  * A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol\n  * Active pregnancy\n  * Restrictions on Use of Other Drugs or Treatments:\n\n    * Any other medication believed to be a contraindication to the subject's participation.","45 Years",{"count":459,"type":21},60,"1 Month","The purpose of this study is to unveil the mechanistic benefits of a bout of postpartum maternal exercise on infant health that are provided by breastmilk.",[463,464,465],"Infant Development","Obesity, Childhood","Diabetes, Childhood-Onset",[467,468],"Breast milk","Postpartum exercise",{"date":302,"type":32},{"date":471,"type":32},"2025-04-21",{"date":473,"type":21},"2028-09-25",{"name":38,"class":39},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":40},"100529820","a-study-of-ai-in-cardiac-transplant-in-echocardiographic-analysis-oracle-100529820","NCT06178744","A Study of AI in Cardiac Transplant in Echocardiographic Analysis (ORACLE)","Outcome Reflection for Immune Mediated Rejection by Utilizing Artificial Intelligence in Cardiac Transplant Patients Through Early and Late Echocardiographic Analysis (ORACLE)","ORACLE","Inclusion Criteria:\n\n* Patients undergoing post-cardiac transplant endomyocardial biopsy, and the ability to provide informed consent and a consent for the study.\n\nExclusion Criteria:\n\n* Refusal of study participation",{"count":484,"type":21},500,"The purpose of this research is to detect episodes of rejection versus non-rejection after cardiac transplant and the diagnostic accuracy of an Artificial Intelligence (AI) algorithm using the data from an ECG (electrocardiogram) and Cardiac Ultrasound (Echocardiogram and\u002For point of care ultrasound).",[487],"Cardiac Transplant Rejection",{"date":302,"type":32},{"date":490,"type":32},"2024-04-04",{"date":492,"type":21},"2028-06",{"name":38,"class":39},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":17,"minAge":501,"maxAge":502,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":40},"100641521","phase-1-aavrh10-pcca-gene-therapy-for-propionic-acidemia-100641521","NCT07643844","AAVrh10-PCCA Gene Therapy for Propionic Acidemia","Phase 1 Study of Intravenous Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Propionyl-CoA Carboxylase cDNA (AAVrh10-PCCA) to Individuals With Propionic Acidemia","Inclusion Criteria:\n\n* Age six months to 2 years of age at day of vector infusion. For those \\\u003C1 year of age they must have been ≥37 weeks gestational age at the time of birth and without other conditions\u002Fcomorbidities that in the opinion of the Investigator may interfere with the interpretation of study results.\n* Confirmed diagnosis of propionic acidemia with biallelic PCCA gene mutations based on molecular genetic testing.\n* Study participants must have a diagnosis of neonatal-onset propionic acidemia with a documented episode of decompensation that can include any of the following findings: lethargy, poor feeding, irritability, vomiting, encephalopathy, respiratory failure, seizures, coma, metabolic acidosis, lactic acidosis, ketonuria, hypoglycemia, hyperammonemia, and cytopenias or history of recurrent hospitalizations.\n* Parents or legal guardians of study participants must agree to comply in good faith with the conditions of the study, including attending all of the required baseline and follow-up assessments, and parents or legal guardians must give consent for their child's participation.\n\nExclusion Criteria:\n\n* Hemoglobin \\\u003C10 g\u002Fdl\n* Platelet count \\\u003C 100,000 per mm3\n* Liver Enzyme ALT\u002FAST \\>2.5 ULN\n* Direct Bilirubin \\> 1.5\n* Active viral infection (includes HIV or serology positive for hepatitis B or C).\n* Previous liver transplant\n* Subjects with active decompensation as demonstrated by a pH \\\u003C 7.3, bicarbonate \\\u003C 15 mmol\u002FL, NH3 \\> 75 mcmol\u002FL, lactate \\> 2.5 mmol\u002FL, urine ketones\n* Previously received gene therapy or messenger ribonucleic acid (mRNA) treatments for PA.\n* Grade 3 or 4 heart failure according to the Modified Ross Heart Failure Classification for Children or the New York Heart Association Classification.\n* Family does not want to disclose patient's study participation with primary care physician and other medical providers.","6 Months","2 Years",{"count":504,"type":21},9,[155],"Propionic acidemia is a genetic metabolic disorder characterized by metabolic acidosis, ketosis, vomiting, lethargy, cognitive impairment, and risk of death. It results from loss of function of the mitochondrial enzyme propionyl-CoA carboxylase and can be due to disease-causing variants in the PCCA gene, leading to accumulation of propionyl-CoA and its toxic metabolites. The purpose of this trial is to evaluate the safety and potential therapeutic benefit of an AAV-based gene therapy for propionic acidemia in patients with genetically confirmed biallelic variants in PCCA.",[508],"Propionic Acidemia","2026-06-18",{"date":300,"type":32},{"date":512,"type":21},"2026-06",{"date":514,"type":21},"2033-12",{"name":38,"class":39},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":22,"phases":525,"briefSummary":527,"conditions":528,"keywords":530,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":538,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":40},"100630449","phase-2-a-study-of-vagal-nerve-stimulation-in-conjunction-with-nrt-for-smoking-cessation-100630449","NCT07487818","A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation","Using Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation","Inclusion Criteria:\n\n* 18 years of age or older at the time of consent.\n* Currently smoking at least 10 cigarettes\u002Fday\n* Motivated to stop smoking (on a scale of 0 to 10, motivation must be 3 or above);\n* Ability to participate fully in all aspects of the study.\n* Have the ability to provide informed consent.\n* Have no contraindicating comorbid health conditions that would interfere with study participation, as determined by the clinical investigators.\n\nExclusion Criteria:\n\n* Patients with a current moderate\u002Fsevere depression as assessed by a score of ≥10 on the Patient Health Questionnaire-9 (PHQ-9).\n* Patients who are or have used an investigational drug within the past 30 days.\n* Patients who are currently using medication(s) known to interact with varenicline.\n* Patients who have clinically significant acute\u002Fchronic progressive or unstable neurologic, hepatic, renal, cardiovascular, psychological, respiratory, or metabolic disease.\n* Patients with a known allergy to nicotine patches or varenicline.\n* Patients with a personal history of acute pancreatitis, hypoglycemia, acute kidney injury or impairment of renal function, type 1 diabetes or diabetic ketoacidosis, and\u002For severe gastrointestinal disease such as gastroparesis.\n* Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device.\n* Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)\n* Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)\n* Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia\n* Patients who have a metallic device such as a stent, bone plate, or bone screw implanted at or near your neck\n* Patients who are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone).\n* Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase but are not willing to use a reliable form of contraception, will also be excluded.\n\n  1. Reliable forms of contraception include oral contraception, diaphragm or condom (with spermicide), injections, intrauterine devices, surgical sterilization, and abstinence. The study does not include vulnerable populations.\n  2. Specifically, the study does not include fetuses, neonates, pregnant women, children (\\\u003C18 years of age), prisoners, institutionalized individuals, or other vulnerable populations.\n\n  i. All female participants of childbearing potential must have a negative pregnancy test and must agree to use approved contraception during study participation.",{"count":524,"type":21},150,[223,526],"PHASE3","The purpose of this study is to provide preliminary evidence for the efficacy of 12 weeks of vagal nerve stimulation (VNS) and nicotine replacement therapy (NRT) for increasing smoking abstinence rates.",[529],"Smoking Cessation",[531,532,533,534,535,536,537],"nicotine dependence","smoking","vagal nerve stimulator","VNS","varenicline","nicotine replacement therapy","nicotine patches",{"date":300,"type":32},{"date":540,"type":32},"2026-04-15",{"date":542,"type":21},"2027-05-31",{"name":38,"class":39},{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":22,"phases":553,"briefSummary":554,"conditions":555,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":557,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":40},"100622093","studying-quality-of-life-inclusive-of-mental-health-and-cognitive-behavioral-therapy-for-cancer-distress-for-the-improvement-of-quality-of-life-in-stage-iii-iv-melanoma-patients-100622093","NCT07379138","Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients","Launching the Era of Melanoma Survivorship: Defining Benchmarks in Quality of Life Inclusive of Mental Health (QOL-MH)","Inclusion Criteria:\n\n* Age \\>= 18-years\n* Stage III-IV melanoma and =\\\u003C 2 month duration of this diagnosis\n* Able to read English sufficient to complete survey, informed consent\n\nExclusion Criteria:\n\n* Does not meet inclusion criteria",{"count":552,"type":21},350,[24],"This clinical trial studies how people feel and live during the first two years after being treated for melanoma and whether cognitive behavioral therapy for cancer distress (CBT-C) works to improve quality of life in patients with stage III-IV melanoma. The melanoma survivorship population is rapidly growing, given the increasing survival rates due to treatment advancements. An urgent need to better define and optimize comprehensive quality of life inclusive of mental health (QOL-MH) has been identified. Cognitive behavioral therapy is a type of psychotherapy that helps patients change their behavior by changing the way they think and feel about certain things. CBT-C is a new type of care that helps patients cope with cancer-related stress, which can include problems like trouble sleeping, trouble focusing, or changes in social life and daily activities. Gathering information on how melanoma patients feel and live during the first two years after treatment may help promote improved care and continued scientific advancements in the understanding of melanoma specific QOL-MH and survivorship as a whole, and may also help determine whether CBT-C improves qualify of life in patients with stage III-IV melanoma.",[556],"Melanoma",{"date":383,"type":32},{"date":559,"type":32},"2025-12-10",{"date":561,"type":21},"2031-12-31",{"name":38,"class":39},""]